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It has been demonstrated that thalidomide’s anti-angiogenic properties result in clear anti-tumor activity in a
number of human malignancies. We studied thalidomide in a human melanoma severe combined immunodeﬁ-
ciency mouse xenotransplantation model. Thalidomide as a single agent showed a significant tumor reduction of
46% compared with the control group. Thalidomide combined with dacarbazine treatment markedly enhanced the
anti-tumor effect of chemotherapy and showed a significant tumor reduction relative to the dacarbazine-only group
(61%) and even more tumor reduction (74%) compared with the control group. We also measured clearly reduced
levels of tumor necrosis factor-a in the thalidomide-treated group. A significantly lower microvessel density was
encountered in the thalidomide treatment groups (thalidomide alone or combined with DTIC), underscoring the
anti-angiogenic effect of thalidomide as a single agent as well as in combination with chemotherapy in this model.
In line with these results, we observed a nearly 3-fold increase of apoptosis for the combination of thalidomide and
DTIC compared with the rate of apoptotic cells in DTIC-only-treated melanoma xenotransplants. These data un-
derline the rationale for combining dacarbazine—a cytotoxic agent—and thalidomide—an anti-angiogenic cyto-
static agent—as a promising strategy for the treatment of melanoma.
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Growth of tumors beyond a few millimeters requires the
induction of new capillary blood vessel. The ability of solid
tumors to induce new blood vessel formations, i.e. angio-
genesis, is therefore crucial for tumor growth and develop-
ment of metastasis. Ample evidence exists that inhibition of
angiogenesis prevents tumor growth; therefore, anti-an-
giogenic therapy seems to be a rational and promising mo-
dality for therapy of human malignant disease (Carmeliet
and Jain, 2000; Folkman, 2001).
Thalidomide (a-N-phtalimidoglutarimide) is a derivative of
glutamic acid. It has a broad spectrum of pharmacological
immunological and other effects, including its well-known
teratogenicity (Franks et al, 2004). The mechanism of action
of thalidomide is complex and not yet completely under-
stood. It has been shown to suppress tumor necrosis fac-
tor-a (TNF-a) production by macrophages in vitro due to
enhancement of the degradation of tumor-necrosis-factor-a
mRNA (Porter and Jorge, 2002).
Recent attention focused on the possibility of using tha-
lidomide as an anti-angiogenic agent (Hales, 1999; Kumar
et al, 2002). D’Amato et al (1994) first demonstrated that
thalidomide exerted anti-angiogenic property in a rabbit
corneal neovascularization assay (D’Amato et al, 1994).
Subsequently, animal studies demonstrated also that tha-
lidomide inhibits tumor-induced angiogenesis in several
cancers (lung cancer, colon cancer, sqamous cell carcino-
ma, esophageal cancer, myeloma) and produces a signif-
icant anti-tumor effect (Kotoh et al, 1999; Myoung et al,
2001; Ruddy and Majumdar, 2002; Yaccoby et al, 2002; Fujii
et al, 2003; Li et al, 2003a, b). In clinical trials, the most
pronounced anti-tumor results were observed in patients
with refractory multiple myeloma (Singhal et al, 1999). But
thalidomide was also studied in further advanced solid
tumors in phase II such as recurrent gliomas, renal cancer,
and hepatocellular carcinoma, showing promising signifi-
cant anti-tumor effects (Fine et al, 2000; Singhal and Mehta,
2002).
Melanoma is a prime example of a tumor with a poor
response to adjuvant therapeutic strategies modalities like
chemotherapy or radiation (Bajetta et al, 2002). Melanomas
are highly vascularized and it has been reported that in-
creased vascularity correlates with poor prognosis (Ribatti
et al, 2003; Valencak et al, 2004). Thalidomide as a single
agent did not show any objective responses in melanoma
patients, but 35% of the patients experienced stable dis-
ease for a duration of 12–32 wk (Eisen et al, 2000; Pawlak
and Legha, 2004). A phase II trial combined treatment of
thalidomide with temozolomide showed promising results.
Abbreviation: DTIC, dacarbazine; SCID, severe combined immuno-
deficiency; TNF-a, tumor necrosis factor a
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In this study, 32% of the melanoma patients had an objec-
tive tumor response (Hwu et al, 2003). This open-labeled
phase II trial, however, was conceptualized as a single-arm
study and did not compare the treatment groups within the
same patient population. The mechanism of thalidomide’s
anti-tumor activity in melanoma remains unclear.
Marriot et al (2003) showed in proliferation assays in vitro
that a panel of tumor cells (colon, pancreatic, prostatic, and
melanoma cells) treated with thalidomide did not exhibit
reduced cell growth. It was also reported that thalidomide
showed no growth inhibition on human colon cells in vitro,
but a growth inhibition of over 40% in a mouse model in vivo
(Kinuya et al, 2002). Only recently, Ansiaux et al (2005)
showed that thalidomide radiosensitizes fibrosarcoma
tumors in mice, whereas the in vitro studies did not dem-
onstrate any growth inhibition or sensitizing effect on fib-
rosarcoma cells.
We therefore focused our studies of thalidomide effects
in melanoma on a well-established in vivo model system. In
this study, we investigated the efficacy of thalidomide in a
xenotransplantation model of human melanoma grown in
severe combined immunodeficiency (SCID) mice. The aim
of this study was to compare the effects of treatment on
melanoma growth with thalidomide, control (carrier solu-
tion), dacarbazine (DTIC), and the combination of thalido-
mide and DTIC. We could demonstrate a clearly more
pronounced effect on tumor growth by the combination of
thalidomide and DTIC over single-agent treatment. This ef-
fect is associated with enhanced induction of apoptosis.
Also, thalidomide treatment led to a significant decrease in
microvessel densitity associated with a decrease of TNF-a
levels.
Results
Tumor growth is reduced by the combination of thalid-
omide and DTIC Subcutaneous injection of human me-
lanoma cells into SCID mice resulted in tumor-take in all
animals inoculated.
Figure 1 shows the tumor volumes of mice treated either
with thalidomide, carrier solution (control), DTIC, or the
combination of DTIC and thalidomide over 22 d (see also
Table I). The growth curve shows a clear difference in the
reduction of tumor volume between the thalidomide and the
control group. The mean tumor volume of the thalidomide
group reached 155.9  59.4 mm3 (mean  SD), which was
46% smaller than the mean tumor volume of the control
group on day 22 (p¼0.014).
On day 22, the tumor volume of the DTIC (only)-treated
group showed a clear tumor reduction (34%) com-
pared with the control (carrier solution) group (187.8
 32.0 mm3). The difference of the mean volume of this
group compared with the control group was also significant
(p¼0.003). Notably, the single-agent thalidomide and DTIC
groups showed no significant differences in tumor volume
(p¼NS).
The combination of thalidomide and DTIC (73.2  23.8
mm3) led to a significant reduction in tumor size on day 22
when compared with all other groups (po0.05). The com-
bination of thalidomide and DTIC showed a 74% tumor size
reduction compared with the control group (p¼0.018).
All the animals tolerated the treatments well. There was
no difference in body weight (data not shown) among the
animals in the various treatment or control groups.
Inhibition of TNF-a plasma level by thalidomide It had
been shown in vitro that thalidomide inhibits TNF-a in sti-
Figure 1
Inhibition of human melanoma growth in svere combined immuno-
deficiency (SCID) mice by the combination of thalidomide and
dacarbazine (DTIC). SCID mice were injected subcutaneously with
2.5  107 human melanoma cells (518 A2) into the lower left flank
(n¼ 10 animals per group). Starting one day after cell inoculation, tha-
lidomide (administered daily at a dose of 400 mg per kg per day) or
carrier solution (control) was administered for 22 d via the intraperito-
neal route. From day 12 to 16, two of four groups also received daily
dacarbazine (80 mg per kg per day i.p.). On day 22, the experiment was
terminated.
Table I. Results of tumor development, microvessel density and apoptosis index of mice (n¼ 10 animals per group), which
received carrier-solution (control), thalidomide, dacarbazineþ carrier-solution, or DTICþ thalidomide at the end of the described
22-d experiments
Treatment
groups (n¼10)
Mean tumor
volume (mm3  SD)
TNF-a Levels
(pg per mL  SD)
Microvessel densitiy
(area per 0.74 mm2)
Rate of
apoptosis (%)
Carrier-solution 286.0  81.2 34.4  17.0 119.8  11.2 0.5  0.2
DTIC 187.8  32.0 13.9  6.2 108.3  11.2 1.8  0.4
Thalidomide 155.9  59.4 41.2  21.1 45.4  23.4 0.8  0.3
ThalidomideþDTIC 73.2  23.8 19.8  1.9 45.3  23.4 5.2  1.2
DTIC, dacarbazine; TNF-a, tumor necrosis factor-a.
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mulated human peripheral monocytes (Sampaio et al,
1992). This inhibitory action was thought to be due to the
enhancement of TNF-a mRNA degradation. Thalidomide
has also been shown to act in the clinic as an anti-TNF-a
agent during TNF-a-mediated diseases (Moreira et al,
1993). We therefore focused on assessing TNF-a and
measured TNF-a plasma levels after 22 d of treatment in
all treatment groups. In accordance with the literature, we
found a clear inhibition (59%) of total TNF-a levels in the
peripheral blood of thalidomide-treated animals compared
to vehicle-treated animals (Fig 2). This difference was not
significant (p¼0.074). TNF-a is known to be elevated by
DTIC in melanoma (Wack et al, 2002). Not surprisingly, we did
observe a clear elevation of TNF-a level in the DTIC single-
agent group (17%) compared to the carrier solution (control)
group. The differences of TNF-a plasma levels between the
DTIC and thalidomide group were over 66% (p¼0.06). The
combination group showed higher TNF-a plasma levels than
the thalidomide group; however, the values measured were
still clearly lower than the ones in the control group.
Inhibition of microvessel density by thalidomide in hu-
man melanoma in SCID mice To gain further insight into
the mechanism of action of thalidomide, we examined sec-
tions of the generated tumors for microvessel density
(Fig 3a). CD31 staining was used as a well-established
marker for microvessels (Myoung et al, 2001; Valencak et al,
2004). The mean number of microvessels of tumors trea-
ted with thalidomide (alone or in combination with DTIC)
was significantly reduced compared with the control (carrier
solution) group and the DTIC group (pp0.05) (Fig 3b). This
significant reduction of microvessel density by thalidomide
indicates the anti-angiogenic potential of thalidomide in this
model system.
Induction of apoptosis by the combination of thalido-
mide and DTIC It is well accepted that DTIC exerts its anti-
tumor activity by induction of apoptosis (Wack et al, 2002).
For thalidomide, the evidence is less clear and somewhat
conflicting. Very recently, it was shown that thalidomide
evokes apoptosis in human blood monocytes in a time- and
concentration-dependent matter (Gockel et al, 2004). In line
with these observations, we determined the number of
apoptotic cells in xenograft tumors treated with thalido-
mide, DTIC, or the combinations of both agents. Thalido-
mide alone as well as carrier solution (control) treatment
showed no clear change in the rate of apoptotic cells com-
pared with the control group (see Fig 4). Single-agent DTIC
resulted in a moderate increase of apoptosis by
1.8%  0.4% SD compared to the control group. The com-
bination group of thalidomide and DTIC, however, showed a
clear increase of 5.2%  1.2% SD of apoptotic cells com-
pared with the control group. Detailed results are summa-
rized in Table I.
Discussion
This study investigates the mechanism of action and the
anti-tumor potential of thalidomide as a single agent and in
combination with DTIC in a xenotransplantation model of
human melanoma.
Even when administered as a single agent, thalidomide
showed a clear tendency to inhibit tumor growth. In con-
sideration of thalidomide’s potential as an adjuvant to
chemotherapy, our data document a clear advantage of the
thalidomide combination therapy over DTIC single-agent
treatment.
A Phase II study of temozolomide plus thalidomide
showed significant clinical activity (Hwu et al, 2003). On the
other hand, temozolomide, a active metabolite of DTIC, did
not show significant differences in the overall response rate
compared with DTIC (Middleton et al, 2000). The results of
Hwu et al (2003) are in line with our findings. Thalidomide
has been reported to use its anti-tumor properties via in-
hibition of angiogenesis in a variety of models of myeloma,
esophageal, lung, colon cancer, and oral squamous cell
carcinoma (Kotoh et al, 1999; Myoung et al, 2001; Yaccoby
et al, 2002; Fujii et al, 2003; Li et al, 2003b). The mechanism
of action in melanoma, however, is only poorly understood.
This study appears to clearly demonstrating the inhibition of
angiogensis by thalidomide in human melanoma. It was the
aim of the study to explore the anti-angiogenic potential of
thalidomide against non-established melanomas resem-
bling the clinical situation of an adjuvant treatment against
micro-metastases after excision of a high-risk primary me-
lanoma. Therefore, we started the treatment with thalido-
mide one day after melanoma cell inoculation. It is of
interest to note that thalidomide mono-therapy using a
comparable administration schedule led to clearly reduced
numbers in lung and liver metastases in a murine xeno-
transplantation model of hepatocellular carcinoma (Zhang
et al, 2005). Several reports link the inhibition of growth
factors like VEGF and bFGF to the anti-angiogenic effect of
thalidomide (Myoung et al, 2001; Li et al, 2003a). In our
study, however, immunohistochemical staining of VEGF and
bFGF did not show any regulation of these factors by
thalidomide (data not shown). In line with our results, no
detectable VEGF or bFGF regulation has been reported
Figure 2
Decrease of tumor necrosis factor-a (TNF-a) level in mouse
serum by thalidomide. Peripheral blood serum levels of TNF-a were
measured after 22 d of treatment (carrier solution (control); thalidomide;
dacarbazine (DTIC); thalidomideþDTIC). Mean TNF-a level  SD,
n¼10.
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in other animal studies despite a clear anti-tumor effect
(Yaccoby et al, 2002; Fujii et al, 2003). It is also reported
that thalidomide blocks the action of VEGF or bFGF on
endothelial cells during angiogenesis rather than blocking
VEGF production/regulation (Amato, 2002; Gelati et al,
2003).
Thalidomide has also been described as an inhibitor of
TNF-a, probably by enhancing the degradation of TNF-a
Figure4
Induction of apoptosis by the
combination of thalidomide and
dacarbazine (DTIC). TUNEL stain-
ing of melanoma tumors grown
in severe combined immunodefi-
ciency (SCID) mice (apoptotic cells
appear fluorescent green; counter-
stain is 40-60-diamidino-2-phenyl-
lin-dole). Representative photo-
graphs of 518A2 tumors treated
with (a), carrier solution (b) thalido-
mide, (c) DTIC, (d) thalidomide/
DTIC, and (e) negative control for
22 d. Original magnification  200.
(f) Higher magnification (  1000) to
confirm apoptotic morphology.
Figure 3
(a) Reduction of microvessel density by thalidomide. (a) Immunohistochemical staining of microvessels in tumor sections with CD31. A, carrier
solution; B, thalidomide; C, dacarbazine (DTIC); D, thalidomide/DTIC. Figure 2 shows a representative example of tumor sections stained with CD31.
The number of stained discrete microvessel in field was counted at  200 magnification. (b) Significant reduction of microvessel in melanoma
tumors by thalidomide. Statistical evaluation of the effect of thalidomide compared with carrier solution (control) on the number of microvessels in
melanoma tumors grown in severe combined immunodeficiency mice. The mean number of microvessels per microscope field (0.74 mm2) was
significantly reduced in the tumors treated with thalidomide and thalidomide combined with DTIC compared with the control group and the DTIC-
only group.
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mRNA ( Moreira et al, 1993; Ching et al, 1995; Argiles et al,
1998). Serum of mice mice treated with single-agent
thalidomide showed a clear reduction of TNF-a compared
with serum of mice in the control group. This finding was
somewhat surprising since most anti-tumor strategies using
the death receptor–ligand TNF tend to facilitate a local in-
crease of TNF around the tumor. An increased level of
mRNA of TNF-a in melanoma was found after treatment
with DTIC (Wack et al, 2002).
Stebbing et al (2001) showed a statistically significant
decrease of TNF-a level in serum in patients with renal
cancer who received high doses of thalidomide and re-
sponded with stable disease or objective response. In our
study, we observed a direct correlation between the de-
crease of TNF-a level in mice serum and the anti-tumor
effect of thalidomide in melanoma. The detailed mechanism
and the significance of this regulation, however, remain to
be elucidated. Recently, it was shown that thalidomide in-
duces apoptosis in monocytes by using a cytochrome c-
dependent pathway (Gockel et al, 2004). Also, thalidomide
treatment resulted in an increase of apoptosis in human T
leukemic cells as evidenced by an increase of caspases-3
activity (Ezell et al, 2003). Furthermore, a novel subclass of
thalidomide analogue (SelCID-3) induced apoptosis in var-
ious tumor cell lines through the induction of G2-M cell cycle
arrest, which in turn led to caspase 3-mediated apoptosis
(Marriott et al, 2003). Surprisingly, in our study, we could not
detect a clear increase of apoptotic cells in the tumors that
were treated with thalidomide alone. The combination of
thalidomide and DTIC, however, resulted in a nearly 3-fold
increase of apoptotic cells (5.2%) compared with tumors
treated with DTIC alone (1.8%). These data indicate that
thalidomide clearly facilitates the induction of apoptosis in-
duced by DTIC in a supra-additive manner. Similarly, the
combination of paclitaxel and thalidomide showed signifi-
cant tumor growth retardation in a human colon cancer
xenograft model. Furthermore, this study noticed a trend of
increased apoptotic index in the combination group (Fujii
et al, 2003).
The concept of either lowering the dose of a given
chemotherapeutic agent or supplementing a particularly
side-effect-prone agent in a combinatorial regime with anti-
angiogenic agents is aimed at improving the effect and tol-
erability of cancer therapy (Verheul et al, 1999). The blocking
of vasculature of tumors can be expected to cause the
death of cells farthest from capillaries, ultimately leading to
a decreased tumor mass and an increased efficiency of
administered chemotherapy drugs. The angiogenesis inhib-
itors could also prevent further growth and progression to
metastatic disease after a chemotherapeutic regimen (Teic-
her et al, 1992; Amato, 2002).
The ability to achieve better anti-tumor responses by
combining dacarbazine—a cytotoxic agent—and thalido-
mide—an anti-angiogenic cytostatic agent—may qualify as
a rational treatment approach to improve the outcome of
melanoma.
Materials and Methods
Thalidomide Thalidomide powder was kindly provided by Gru-
nenthal (Aachen, Germany). It was suspended in 1% carboxyme-
thylcellulose (CMC), 0.1% Tween 80, and phosphate-buffered
saline (PBS, Gibco BRL, Paisley, Scotland) by extensive stirring.
Cell culture The human melanoma cell line 518 A2 (Jansen et al,
1998) was maintained in basal tissue culture medium (DMEM,
Gibco BRL) supplemented with 8% fetal calf serum (FCS) and an-
tibiotics, in a humidified 5% CO2, 95% ambient air atmosphere of
371C.
Experimental animals and tumor treatment in SCID mice Path-
ogen-free female C.B-17 scid/scid (SCID) mice, 4–6 wk old, were
obtained from Bomholtgard Breeding and Research Center
(Bomice, Denmark) and randomly assigned to the experimental
groups. The animals were housed in laminar flow racks and micro-
isolator cages under specific pathogen-free conditions and re-
ceived autoclaved food and water, but no antibiotic prophylaxis.
SCID mice (n¼ 40) were injected subcutaneously with 2.5  107
human melanoma cells (518 A2) into the lower left flank. Four
groups (n¼ 10 animals per group) were stratified to receive either
(1) thalidomideþ carrier solution; (2) carrier solution; (3) da-
carbazineþ carrier solution; and (4) dacarbazineþ thalido-
mideþ carrier solution. One day after cell inoculation, groups 1
and 4 received thalidomide via the intraperitoneal route at a dose
of 400 mg per kg per day (Ruddy and Majumdar, 2002) for 22 d.
Groups 2 and 3 also received daily injections for 22 days, but of the
carrier solution (control). From day 12 to 16, groups 3 and 4 ad-
ditionally received dacarbazine (80 mg per kg per day) intraperi-
toneally on a daily basis. The length and width of the subcutaneous
tumors were measured using a caliper twice a week (volume
(mm3)¼ length  width2). On day 22, blood was collected and the
experiment was terminated. This study was approved by the Med-
ical University of Vienna’s animal welfare committee.
Quantitative estimate of human TNF-a by ELISA Levels of TNF-
a in serum were determined using an ELISA (Quantikine Mouse
TNF-a kit; R&D Systems, Minneapolis, Minnesota) according to the
manufacturer’s instructions. Briefly, serum samples were added to
microwells coated with monoclonal antibodies against the cytokine
measured. After incubation, wells were washed and then an en-
zyme-linked polyclonal anti-TNF-a antibody was added. Following
a new incubation and a subsequent wash that removed any un-
bound antibody-enzyme reagent, substrate was added. After in-
cubation, an amplifier solution was added, leading to color
development. Absorbance was measured at 450 nm, and the re-
sults were calculated from a standard curve produced by serial
dilutions of a given cytokine sample.
Histopathological examination For histopathology studies, mac-
roscopically normal tissues (brain, lung, heart, liver spleen, kidney,
and small intestine) and tumor tissue were obtained from all an-
imals, and then fixed in 7.5% neutral-buffered formalin, dehydrat-
ed, and embedded in paraffin using routine methods. Glass slides
with 5 mm tissue sections were prepared and stained with hem-
atoxylin and eosin. Additional tumor tissue was frozen and used for
immunohistological stainings that were performed with the use of
the avidin–biotin–peroxidase complex method. Hamster anti-
mouse polyclonal antibody (Endogen, Boston, Massachusetts)
was used for CD31 (PECAM). 5 mm frozen tumor sections were
incubated with the primary antibody (dilution 1:75) at room tem-
perature for 1 h. The subsequent steps were carried out using
LSAB Kit (DAKO, Glostrup, Denmark) with a second biotin-conju-
gated anti-hamster antibody (DAKO).
Microvessel count The CD31-stained sections were scanned at a
low magnification to identify the highest vascular area, and three
fields were chosen for further assessment. The numbers of stained
discrete microvessels/field were counted at  200 magnification
(0.74 mm2 per area). Vessel counting was performed in a blinded
manner. Average vessel numbers in three fields as well as the
mean vessel number and SD of each group were calculated.
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Evaluation of apoptosis TdT-mediated dUTP nick end-labeling
(TUNEL) immunohistochemistry was performed in tumor xeno-
transplants according to the manufacturer’s protocol (Roche
Diagnostics, Mannheim, Germany). Only comparable sections of
the outer layers of the tumors without signs of necrotic areas were
analyzed. The apoptotic index was determined by fluorescence
microscopy blinded to the treatment groups.
Statistical analysis Statistical significance of differences between
treatment groups was calculated by using one-way ANOVA and
post-test comparing means using the Bonferroni’s test for post hoc
testing (SPSS, Chicago Illinois). p-Values of p0.05 were consider-
ed to be of statistical significance.
We thank Helga Pischinger for excellent animal care. We are very
grateful to Grunenthal, Aachen, who kindly provided Thalidomide
powder. This work was supported by the ‘‘Austrian National Bank’’, the
‘‘Hans und Blanka Moser Stiftung’’, the ‘‘Niarchos Foundation’’,
the ‘‘Hygiene Fund’’, the ‘‘Virology Fund’’, and the ‘‘Kamillo Eisner
Stiftung’’.
DOI: 10.1111/j.0022-202X.2005.23830.x
Manuscript received November 30, 2004; revised March 7 2005;
accepted for publication March 15, 2005
Address correspondence to: Elisabeth Heere-Ress, MD, Department
of Dermatology, Division of General Dermatology, Vienna General Hos-
pital/ University of Vienna, Waehringer Guertel 18-20; A-1090 Vienna,
Austria. Email: Elisabeth.Heere-Ress@akh-wien.ac.at
References
Amato RJ: Thalidomide: An antineoplastic agent. Curr Oncol Rep 4:56–62, 2002
Ansiaux R, Baudelet C, Jordan BF, et al: Thalidomide radiosensitizes tumors
through early changes in the tumor microenvironment. Clin Cancer Res
11:743–750, 2005
Argiles JM, Carbo N, Lopez-Soriano FJ: Was tumour necrosis factor-alpha re-
sponsible for the fetal malformations associated with thalidomide in the
early 1960s? Med Hypotheses 50:313–318, 1998
Bajetta E, Del Vecchio M, Bernard-Marty C, et al: Metastatic melanoma: Chem-
otherapy. Semin Oncol 29:427–445, 2002
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature
407:249–257, 2000
Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC: Effect of
thalidomide on tumour necrosis factor production and anti-tumour activ-
ity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer
72:339–343, 1995
D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of
angiogenesis. Proc Natl Acad Sci USA 91:4082–4085, 1994
Eisen T, Boshoff C, Mak I, et al: Continuous low dose Thalidomide: A phase II
study in advanced melanoma, renal cell, ovarian and breast cancer. Br J
Cancer 82:812–817, 2000
Ezell TN, Maloney N, Githua JW, Taylor LD: Exposure to the anti-TNF-alpha drug
thalidomide induces apoptotic cell death in human T leukemic cells. Cell
Mol Biol (Noisy-le-grand) 49:1117–1124, 2003
Fine HA, Figg WD, Jaeckle K, et al: Phase II trial of the antiangiogenic agent
thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol
18:708–715, 2000
Folkman J: Angiogenesis-dependent diseases. Semin Oncol 28:536–542, 2001
Franks ME, Macpherson GR, Figg WD: Thalidomide. Lancet 363:1802–1811,
2004
Fujii T, Tachibana M, Dhar DK, et al: Combination therapy with paclitaxel and
thalidomide inhibits angiogenesis and growth of human colon cancer
xenograft in mice. Anticancer Res 23:2405–2411, 2003
Gelati M, Corsini E, Frigerio S, et al: Effects of thalidomide on parameters in-
volved in angiogenesis: An in vitro study. J Neurooncol 64:193–201, 2003
Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T,
Lugering N: Thalidomide induces apoptosis in human monocytes by us-
ing a cytochrome c-dependent pathway. J Immunol 172:5103–5109,
2004
Hales BF: Thalidomide on the comeback trail. Nat Med 5:489–490, 1999
Hwu WJ, Krown SE, Menell JH, et al: Phase II study of temozolomide plus
thalidomide for the treatment of metastatic melanoma. J Clin Oncol
21:3351–3356, 2003
Jansen B, Schlagbauer-Wadl H, Brown BD, et al: bcl-2 antisense therapy
chemosensitizes human melanoma in SCID mice. Nat Med 4:232–234,
1998
Kinuya S, Kawashima A, Yokoyama K, et al: Cooperative effect of radioimmuno-
therapy and antiangiogenic therapy with thalidomide in human cancer
xenografts. J Nucl Med 43:1084–1089, 2002
Kotoh T, Dhar DK, Masunaga R, et al: Antiangiogenic therapy of human es-
ophageal cancers with thalidomide in nude mice. Surgery 125:536–544,
1999
Kumar S, Witzig TE, Rajkumar SV: Thalidomide as an anti-cancer agent. J Cell
Mol Med 6:160–174, 2002
Li X, Liu X, Wang J, et al: Effects of thalidomide on the expression of angiogenesis
growth factors in human A549 lung adenocarcinoma cells. Int J Mol Med
11:785–790, 2003a
Li X, Liu X, Wang J, et al: Thalidomide down-regulates the expression of VEGF
and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer
Res 23:2481–2487, 2003b
Marriott JB, Clarke IA, Czajka A, et al: A novel subclass of thalidomide analogue
with anti-solid tumor activity in which caspase-dependent apoptosis is
associated with altered expression of bcl-2 family proteins. Cancer Res
63:593–599, 2003
Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of
temozolomide versus dacarbazine in the treatment of patients with
advanced metastatic malignant melanoma. J Clin Oncol 18:158–166,
2000
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalid-
omide exerts its inhibitory action on tumor necrosis factor alpha by en-
hancing mRNA degradation. J Exp Med 177:1675–1680, 1993
Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ: Evaluation of the anti-tumor and
anti-angiogenic effect of paclitaxel and thalidomide on the xenotrans-
planted oral squamous cell carcinoma. Cancer Lett 163:191–200, 2001
Pawlak WZ, Legha SS: Phase II study of thalidomide in patients with metastatic
melanoma. Melanoma Res 14:57–62, 2004
Porter SR, Jorge J Jr: Thalidomide: A role in oral oncology? Oral Oncol 38:
527–531, 2002
Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P: Tumor vas-
cularity and tryptase-positive mast cells correlate with a poor prognosis in
melanoma. Eur J Clin Invest 33:420–425, 2003
Ruddy JM, Majumdar SK: Antitumorigenic evaluation of thalidomide alone and in
combination with cisplatin in DBA2/J mice. J Biomed Biotechnol 2:7–13,
2002
Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G: Prolonged treatment
with recombinant interferon gamma induces erythema nodosum
leprosum in lepromatous leprosy patients. J Exp Med 175:1729–1737,
1992
Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother 56:4–12, 2002
Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refrac-
tory multiple myeloma. N Engl J Med 341:1565–1571, 1999
Stebbing J, Benson C, Eisen T, et al: The treatment of advanced renal cell cancer
with high-dose oral thalidomide. Br J Cancer 85:953–958, 2001
Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cyto-
toxic cancer therapies against primary and metastatic disease. Cancer
Res 52:6702–6704, 1992
Valencak J, Heere-Ress E, Kopp T, Schoppmann SF, Kittler H, Pehamberger
H: Selective immunohistochemical staining shows significant prognostic
influence of lymphatic and blood vessels in patients with malignant
melanoma. Eur J Cancer 40:358–364, 2004a
Verheul HM, Panigrahy D, Yuan J, D’Amato RJ: Combination oral antiangiogenic
therapy with thalidomide and sulindac inhibits tumour growth in rabbits.
Br J Cancer 79:114–118, 1999
Wack C, Kirst A, Becker JC, Lutz WK, Brocker EB, Fischer WH: Chemoimmuno-
therapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene
elicits a specific T cell-dependent immune response. Cancer Immunol
Immunother 51:431–439, 2002
Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein
J: Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood
100:4162–4168, 2002
Zhang ZL, Liu ZS, Sun Q: Effects of thalidomide on angiogenesis and tumor
growth and metastasis of human hepatocellular carcinoma in nude mice.
World J Gastroenterol 11:216–220, 2005
206 HEERE-RESS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
